Factor VIII products and inhibitor development in severe hemophilia A. - Wikidata - wikimedia - TriplyDB

Factor VIII products and inhibitor development in severe hemophilia A.

Factor VIII products and inhibitor development in severe hemophilia A.

http://www.wikidata.org/entity/Q43770114

about

Rituximab for treating inhibitors in people with inherited severe hemophilia Desmopressin acetate (DDAVP) for preventing and treating bleeding in people with mild or moderate haemophilia A Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B Rituximab for treating inhibitors in children with hemophilia Potential role of a new PEGylated recombinant factor VIII for hemophilia A.Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity Switching treatments in haemophilia: is there a risk of inhibitor development?Present and future challenges in the treatment of haemophilia: the patient's perspective Present and future challanges in the treatment of haemophilia: a clinician's perspective FVIII inhibitors: pathogenesis and avoidance Progress and challenges in the development of a cell-based therapy for hemophilia A Reversal of direct oral anticoagulants in hemophilia treatment: ASH meeting 2015 Different impact of factor VIII products on inhibitor development?Large scale studies assessing anti-factor VIII antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more.SIPPET: methodology, analysis and generalizability.The current state of adverse event reporting in hemophilia.The safety of pharmacologic options for the treatment of persons with hemophilia.A new recombinant factor VIII: from genetics to clinical use.Current and evolving features in the clinical management of haemophilia Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011 Production of factor VIII by human liver sinusoidal endothelial cells transplanted in immunodeficient uPA mice.AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice.Design of the INHIBIT trial: preventing inhibitors by avoiding 'danger', prolonging half-life and promoting tolerance.Patient data meta-analysis of Post-Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF-PFM.Profile of efraloctocog alfa and its potential in the treatment of hemophilia A.Addressing prior-data conflict with empirical meta-analytic-predictive priors in clinical studies with historical information.Transgene-host cell interactions mediate significant influences on the production, stability, and function of recombinant canine FVIII Issues in pediatric haemophilia care Evaluation of the biological differences of canine and human factor VIII in gene delivery: implications in human hemophilia treatment.High rate of spontaneous inhibitor clearance during the long term observation study of a single cohort of 524 haemophilia A patients not undergoing immunotolerance.Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.Risk factors for high-titer inhibitor development in children with hemophilia A: results of a cohort study.Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models.Clinical use of factor VIII and factor IX concentrates Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.Plasma exchange and immunosuppressive therapy in a case of mild haemophilia A with inhibitors and a life-threatening lower limb haemorrhage.

P2860

Q24186623-A216AC0B-43CC-47D4-A278-E4CB30701D48 Q24187454-06ADA180-49C2-4708-A410-C9DF6CC88BA7 Q24195006-DBE37F37-A2D5-457E-AF47-260D67C3AA6E Q24197700-B91DB908-3D99-42BA-9A58-0F44A7A2FFE9 Q26744309-F8A42EE1-B1A7-43BC-AEC8-03D3C096E1D2 Q26866323-65CF3603-5CFD-4B82-91AA-3A4B89CC51C5 Q27001016-40A55B2C-BBBB-4D86-A8F9-E08E9985BE44 Q27022801-D8BC5D96-4601-4B68-A22C-80C06AA406A0 Q27026137-5DD8E3A3-F454-457C-B4AD-19AC8A93DF2D Q27027224-D7272F4D-A021-4931-964E-CBDF6AB47628 Q27027298-7CA07E7B-F914-4A55-9BA3-89A8D230A53E Q28072261-253CAB87-506F-4C57-921A-320287816C3A Q28075679-3E148925-D7C9-485D-B710-D42247E03359 Q30234910-0C318459-E299-43A8-AB7C-D75150ADF25E Q30235225-3219D7FF-F3B1-413F-972B-E97EB5FB0546 Q30239952-7FBFA975-6D35-484F-A95A-E08296E719A5 Q30249200-D984C90D-DB89-47F2-A088-DDE15F4F26BC Q30370282-1A50E3A8-A439-49D2-9D18-47C2C5782DF8 Q33708976-FAA5DAA8-FE66-4456-A051-3EE949EC8FAD Q33820925-7315A15A-4794-49B4-B20D-6DA68240867C Q33841435-B22BF47A-966C-45BC-BD4E-19ADB8140EAF Q34200694-9442B4BC-631A-4849-B793-CB45B8BF9391 Q34416394-2130F6B2-F85B-4F2C-80B0-3B2D16996702 Q34580100-BD5A923C-1F10-47DD-9993-33566D1B7BCE Q35027719-990BA7B4-DE35-4661-9934-13B10CE5E952 Q35153203-E47BAAC2-4012-444D-A3DA-1593FD6925A2 Q35168244-3E1097D3-6405-4F79-920A-07C96E2E2D14 Q35209354-BC9ED79B-CBC7-4BD0-8C07-6953A7C5434D Q35565320-21955F6D-B6B7-4D1F-9EF5-39132450391D Q36107914-CB9349D4-3EBA-4DD1-A4F2-4811C1288EE3 Q36294629-0F2B3EE8-D832-412A-ACB3-C0BEC25DEF8C Q36835166-BEE86FAF-E0AC-4110-B69C-F35B14D74EAA Q37075305-FC1008FF-CC33-4146-B876-12E07CF58D28 Q37153668-835458B9-13D1-41A9-9D94-32E602708EBD Q37185097-FD98D303-9206-466C-9EAE-9A63B315B507 Q37253340-476C4FD2-ED97-4AB3-B5F2-1F3007BB0465 Q37316242-524D5557-1D32-4D59-8A61-E69FF23F8E08 Q37370356-6BF8CC26-03BD-4493-A3C7-8D3A6D8D5C6C Q37489013-DB04B378-BF0A-4678-ACB5-726ABE4D19EF Q37588914-C33F16C1-C5C6-4338-AEE1-BE511C246357

P2860

Factor VIII products and inhibitor development in severe hemophilia A.

http://www.wikidata.org/entity/Q43770114

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Factor VIII products and inhibitor development in severe hemophilia A.

@en

Factor VIII products and inhibitor development in severe hemophilia A.

@nl

type

label

Factor VIII products and inhibitor development in severe hemophilia A.

@en

Factor VIII products and inhibitor development in severe hemophilia A.

@nl

prefLabel

Factor VIII products and inhibitor development in severe hemophilia A.

@en

Factor VIII products and inhibitor development in severe hemophilia A.

@nl

P1433

Q43770114-FA7022D5-6670-4EE9-9BF7-792EFFCABAEA

P1476

Q43770114-938F5EB3-9B09-46FE-9CDA-BE473920EB0E

P2093

Q43770114-09BF6258-E7D6-4C8F-B6C2-1252BD1E17CB

Q43770114-0DE00E18-1E50-48AF-A5A5-44629EBC1D3F

Q43770114-171F11E5-5C11-4F82-8920-6ECE995A77BA

Q43770114-25059504-156C-49A1-B10D-58A8F1A517C8

Q43770114-28E8E176-B868-4535-B39F-8287AC141926

Q43770114-2D9A1ACC-0980-44FB-AECD-3ED67861CC76

Q43770114-4158EC44-8403-47D9-8284-FC0634068BEB

Q43770114-7006737D-66FE-4CB2-B889-5C3EF06CE38E

Q43770114-7167A1C6-30F3-4154-94E2-081B3DED0F14

Q43770114-89E88221-460A-4917-9636-1BFE7DA74B91

P304

Q43770114-75400E75-454E-47DA-B74E-7C2E460E7E67

P31

Q43770114-F3C58295-3141-4A15-86F4-868FBDFDDCEC

P356

Q43770114-33A3CEFF-4A80-4D9C-9095-F318A0FD86CA

P407

Q43770114-77CDF2F2-31F3-4C93-8E59-0317D918B2F9

P433

Q43770114-5AA541B4-BD19-4C7B-A195-E4CEF9D53114

P478

Q43770114-6B92E3AE-5C2E-48FD-941E-4827D4D88101

P50

Q43770114-3D177154-7A7E-4CCD-85D8-534F6234BF20

Q43770114-B285421E-43D0-4791-8360-91EA7D377D2E

Q43770114-c5a82ec8-485d-accc-a3dd-c7047735e9b0

P577

Q43770114-A8698D14-3941-4970-87E5-6A51E69A6EA8

P698

Q43770114-27B01004-A9F4-4317-B8FF-96842C79CE10

P921

Q43770114-568904B0-F367-4AAA-A15C-4DD484E863E2

Q43770114-CE13AB2F-80F4-4CF2-A1BA-5365407F3349

Q43770114-EF7F6EEF-EEA6-4181-BA29-95A2CC77EAA1

P356

P1433

The New England Journal of Medicine

P1476

Factor VIII products and inhibitor development in severe hemophilia A.

@en

P2093

Ana R Cid

http://www.w3.org/2001/XMLSchema#string

Angela Thomas

http://www.w3.org/2001/XMLSchema#string

Anne Mäkipernaa

http://www.w3.org/2001/XMLSchema#string

Carmen Escuriola

http://www.w3.org/2001/XMLSchema#string

Christel van Geet

http://www.w3.org/2001/XMLSchema#string

Elena Santagostino

http://www.w3.org/2001/XMLSchema#string

George Rivard

http://www.w3.org/2001/XMLSchema#string

Gili Kenet

http://www.w3.org/2001/XMLSchema#string

H Marijke van den Berg

http://www.w3.org/2001/XMLSchema#string

PedNet and RODIN Study Group

http://www.w3.org/2001/XMLSchema#string

P304

231-239

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1208024

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

368

http://www.w3.org/2001/XMLSchema#string

P50

Johanna G van der Bom

Angelo Claudio Molinari

Carmen Escuriola Ettingshausen

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23323899

http://www.w3.org/2001/XMLSchema#string

P921

Coagulation factor VIII